Navigation Links
Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors
Date:4/15/2008

GLASGOW, Scotland, April 15 /PRNewswire/ -- Excalibur, the new international investment house launched by Sir Christopher Evans, today (Tuesday) welcomed the sale of PIramed to Roche.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 )

The sale of PIramed to Roche for $185 million means a 'very substantial cash return' to investors in Merlin III, the investment fund created by Sir Christopher five years ago.

Merlin Biosciences were co-founding investors in PIramed at the outset in 2003 with JP Morgan. Merlin, with the founders of the company, also selected the CEO, the management team, built the board of directors and continued to provide ongoing funding and strategic advice to the company.

Sir Christopher Evans said: "The sale is terrific news for everyone who has been associated with PIramed since the early days. It is complete vindication of the founders' vision and also the flawless execution of a scientific, management and investment plan that Merlin and JP Morgan stuck to from the outset. We are delighted to have been involved from day one and at Excalibur we are pleased to be delivering to investors in our Merlin Fund III such a substantial return on their investment."

Notes to Editors:

Excalibur has been founded by Professor Sir Christopher Evans and is a major new development of the original Merlin Biosciences business. Merchant Ventures, a specialist financial services group, was acquired to create Excalibur.

Excalibur is following the successful investment strategy of Merlin's Fund III which has focused more broadly on healthcare and medical science investments and is already delivering significant returns to investors with five more years to run.

The three existing Merlin investment funds operate under their original titles within the Excalibur group.

Key investors and stakeholders in Excalibur besides Sir Chris include Sir Tom Hunter's West Coast Capital, Professor Jeremy Stone, chairman of Merchant Ventures, and Lloyds TSB.

Further information:

Ramsay Smith,

Media House International.

Tel +44(0)207-397-8460/+44(0)7788-414856.

Email:ramsay@mediahouse.co.uk


'/>"/>
SOURCE Excalibur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
2. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
3. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
4. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
5. Guava Technologies Celebrates Tenth Anniversary
6. New Enterprise Forum Celebrates 22nd Anniversary, Presents Annual Entrepreneur Awards to Randal Charlton & Others
7. Winnick Family Clinical Research Center Celebrates 6th Anniversary
8. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
9. HCM Announces Substantial Growth in 2007
10. Cystic Fibrosis Trial In Children Returns Positive Data
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):